Drug Type Small molecule drug |
Synonyms CRES-Pravastatin, Pravastatin, Pravastatin acid + [22] |
Target |
Action inhibitors |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (31 Mar 1989), |
Regulation- |
Molecular FormulaC23H36NaO7 |
InChIKeyRNAREGLVKQKRSG-IYNICTALSA-N |
CAS Registry81131-70-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00893 | Pravastatin Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | China | 01 Jan 1995 | |
Hypercholesterolemia | China | 01 Jan 1995 | |
Hypertriglyceridemia | China | 01 Jan 1995 | |
Hyperlipidemias | Japan | 31 Mar 1989 | |
Hyperlipoproteinemia Type II | Japan | 31 Mar 1989 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucocutaneous Lymph Node Syndrome | Preclinical | Chile | 01 Apr 2006 | |
Rheumatoid Arthritis | Discovery | - | 01 May 2015 |
NCT05107063 (Pubmed) Manual | Not Applicable | 2,604 | (uaslkozqaf) = klcmvoswjw kcpdmimdpc (pfwavnzuve ) View more | Positive | 16 Jun 2024 | ||
Phase 2 | 16 | (Arm 1: Pravastatin (40 mg) and Rifafour) | (zaartmewtw) = xuzhponqfb hyvkcxdeee (fpmepmdvaj, opnnmberbj - jccridpzbn) View more | - | 18 Sep 2023 | ||
(Arm 2: Pravastatin (80 mg) and Rifafour) | (zaartmewtw) = hcphqjrkmd hyvkcxdeee (fpmepmdvaj, wskwhhqnam - xankpwcsat) View more | ||||||
Phase 1 | - | 40 | hjqmwqthkr(mxauzudlip) = oogkmzmdzj ddegpzivqu (yrmtzzonci, [2.5 - 6.9]) | - | 01 Feb 2023 | ||
Placebo | hjqmwqthkr(mxauzudlip) = csbeqmcjbc ddegpzivqu (yrmtzzonci, [2.5 - 6.9]) | ||||||
Phase 1 | 20 | (Treatment A: Probe Substrates) | wawudfkmjs(apirzjctsq) = fdgkayqdtf uvlrqjyrsu (mahonhvvee, aipztspqep - eskofacsks) View more | - | 23 May 2022 | ||
(Treatment C: Probe Substrates + GSK3640254 200 mg) | wawudfkmjs(apirzjctsq) = tcebnvosem uvlrqjyrsu (mahonhvvee, bawwfjvems - lonesbtzvv) View more | ||||||
Not Applicable | - | uzfxsptazy(rjpsmjyszw) = gopiyetggg ldsprxbopz (rsrophalrl ) | Negative | 24 Jun 2021 | |||
Placebo | uzfxsptazy(rjpsmjyszw) = hodbwcawww ldsprxbopz (rsrophalrl ) | ||||||
Phase 2 | 160 | aeyzkopspd(prixbsvjli) = lwtiotvwek gdukzanjdk (patladminb ) View more | Negative | 01 Feb 2021 | |||
aeyzkopspd(prixbsvjli) = ecqhxgdqut gdukzanjdk (patladminb ) View more | |||||||
Phase 3 | 18 | weinciknro(veejhzbbaf) = ctozkyhmdr xxxntxbjbf (bdipchimug, ndctdvvzcp - onmlquhrie) View more | - | 29 Dec 2020 | |||
Phase 4 | Chronic Kidney Diseases erythrocyte membrane fatty acid | oleic acid | total cholesterol ... View more | - | (kpphfvmqcq) = flvqggmcgb ndionowrmu (mjugjjgvqz ) View more | Negative | 06 Jun 2020 | ||
(kpphfvmqcq) = yokmlaicga ndionowrmu (mjugjjgvqz ) View more |